Drug updated on 12/11/2024
| Dosage Form | Injection (intraocular: 0.025%) |
| Drug Class | Disclosing agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated to selectively stain the internal limiting membrane (ILM).
Latest News
Summary
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- The use of Brilliant Blue G (BBG) for internal limiting membrane peeling in macular hole surgery resulted in a significant improvement in postoperative best corrected visual acuity (BCVA) compared to Indocyanine Green (ICG), with a weighted mean difference (WMD) of 0.08 (95% confidence interval (CI): 0.01-0.16), while Triamcinolone Acetonide (TA) showed the highest BCVA improvement overall.
- BBG was associated with the highest postoperative primary macular hole closure rates, particularly for idiopathic macular hole (IMH), with a significant difference in closure rates compared to no dye, although no significant differences were found between any two groups overall.
- Both studies focused on patients undergoing macular hole surgery, specifically those with IMH, with no subgroup analyses based on age, gender, or comorbid conditions reported.
- There is no safety information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| TissueBlue (brilliant blue g ophthalmic solution) Prescribing Information. | 2019 | Dutch Ophthalmic USA, Exeter, NH |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Outcomes of 4 surgical adjuvants used for internal limiting membrane peeling in macular hole surgery: a systematic review and network Meta-analysis | 2020 | International Journal of Ophthalmology |
| Internal limiting membrane peeling with different dyes in the surgery of idiopathic macular hole: a systematic review of literature and network Meta-analysis | 2019 | International Journal of Ophthalmology |